SARS-CoV 2 Virus Causing Fulminant Myocarditis: A Rare but Serious Complication of COVID-19 Infection

Abou Dargham Hanadi¹, Brar Rajvir^1, , Dadashzadeh Shima², Hanna Mena³ and Chong Josebelo⁴

¹Family Medicine Residency Program, St. Joseph’s Medical Center, Stockton, CA, 95204, USA

²Touro University College of Medicine 1310 Club Dr, Vallejo, CA 94592

³American University of Antigua College of Medicine Jabberwock Rd, Osbourn, Antigua & Barbuda

⁴San Joaquin Critical Care Medical Group, St. Joseph’s Medical Center, Stockton, CA, 95204, USA

Cite this paper

Abou Dargham Hanadi, Brar Rajvir, Dadashzadeh Shima, Hanna Mena and Chong Josebelo. SARS-CoV 2 Virus Causing Fulminant Myocarditis: A Rare but Serious Complication of COVID-19 Infection. American Journal of Medical Case Reports. 2022; 10(9):218-223. doi: 10.12691/AJMCR-10-9-2

Abstract

The COVID-19 pandemic has been one that has brought widespread suffering and grief throughout the world; and the complications associated-both short and long term have been widespread and autonomous. We present a case of a 68-year-old White Hispanic male who presented to the emergency department with worsening exertional dyspnea and fatigue eight days after testing positive for SARS-CoV-2. On arrival the patient was afebrile, hypotensive, tachycardic, tachypneic and hypoxemic. Initial workup was significant for high elevated inflammatory markers, troponin and β-natriuretic peptide. EKG was unremarkable. Transthoracic echocardiogram revealed severe global hypokinesis of the left ventricle, reduced ejection fraction of 25%-30%, grade II diastolic dysfunction, mild pulmonary hypertension and mild elevated right atrial pressures, and no pericardial effusion. PCR analysis for usual cardiotropic viruses were all negative, Antinuclear antibody (ANA) was negative, therefore the patient was diagnosed with fulminant COVID-19 myocarditis. Patient was treated with heparin drip, oxygen support, pressors, and high dose corticosteroid therapy in the intensive care unit for 5 days. After showing significant signs of improvement, the patient was discharged on hospital stay day 7. Cardio-respiratory complications are the leading cause of morbidity and mortality in terms of patients suffering with COVID-19. In this case we discuss the importance of early diagnosis and prompt management to reduce the high mortality and complications associated with these complications.

Keywords

Covid-19, myocarditis, SARS-CoV-2, complications, cardiac

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	US Coronavirus Case and Deaths. (2020). USA FACTS. https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/.
[2]	Sawalha K, Abozenah M, Kadado AJ, Battisha A, Al-Akchar M, Salerno C, Hernandez-Montfort J, Islam AM. Systematic review of COVID-19 related myocarditis: Insights on management and outcome. Cardiovasc Revasc Med. 2020 Aug 18. pii: S1553-8389(20)30497-8.
[3]	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. The RECOVERY Collaborative Group. The New England Journal of Medicine. NEJMoa2021436PMCID: PMC7383595, PMID: 32678530.
[4]	Knowlton KU. Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. J Mol Cell Cardiol. 2020 Oct; 147: 12-17.
[5]	Tucker NR, Chaffin M, Bedi KC Jr, Papangeli I, Akkad AD, Arduini A, Hayat S, Eraslan G, Muus C, Bhattacharyya RP, Stegmann CM; Human Cell Atlas Lung Biological Network., Margulies KB, Ellinor PT; Human Cell Atlas Lung Biological Network Consortium Members.. Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis. Circulation. 2020 Aug 18; 142(7): 708-710.
[6]	Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink HM, Smits PC, Tieleman RG, van der Harst P, van Gilst WH, Asselbergs FW; CAPACITY-COVID collaborative consortium. Cardiac complications in patients hospitalised with COVID-19. Eur Heart J Acute Cardiovasc Care. 2020 Dec; 9(8): 817-823.
[7]	Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020 Jun 9; 141(23): 1903-1914.
[8]	Stöbe S, Richter S, Siege M, Stehr S, Laufs U, Hagendorff A. Echocardiographic characteristics of patients with SARS-CoV-2 infection. Clin Res Cardiol. 2020 Dec; 109(12): 1549-1566.
[9]	Jacquet-Lagrèze M, Riad Z, Hugon-Vallet E, Ferraris A, Fellahi JL. Left ventricular dysfunction in COVID-19: A diagnostic issue. Anaesth Crit Care Pain Med. 2020 Jun; 39(3): 393-394.
[10]	Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco T, Camporotondo R, Bruno R, Baldanti F, Paolucci S, Pelenghi S, Iotti GA, Mojoli F, Arbustini E. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020 May; 22(5): 911-915.
[11]	Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, De Ferrari GM. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020 Aug; 106(15): 1127-1131.
[12]	Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, Wang LF, Gao H, Wang Y, Dong CF, Li YJ, Xie XJ, Feng C, Liu L. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Oct; 48(5): 773-777.
[13]	Sheposh R. Coronavirus Disease 2019 (COVID-19). Salem Press Encyclopedia of Health. 2021.
[14]	Bernal-Torres W, Herrera-Escandon A, Hurtado-Rivera M, Plata-Mosquera CA. COVID-19 Fulminant Myocarditis: A Case Report. European Society of Cardiology. European Heart Journal 8 July 2020 4, 1-6.
[15]	Chen C, Li H, Hang W, Wang DW. Cardiac injuries in coronavirus disease 2019 (COVID-19). Journal of molecular and cellular cardiology. 2020; 145: 25-29.
[16]	Ho, JSY, Ching,-Hui S, Chan MYY, Lin, W, Wong RCC. Coronavirus-induced myocarditis: A met-summary of cases. Heart and Lung.
[17]	Salamanca J, Díez-Villanueva P, Martínez P, Cecconi A, González de Marcos B, Reyes G, Salas C, Segovia J, Jiménez-Borreguero LJ, Alfonso F. COVID-19 “Fulminant Myocarditis” Successfully Treated With Temporary Mechanical Circulatory Support. JACC Cardiovasc Imaging. 2020 Nov; 13(11): 2457-2459.
[18]	Mavrogeni S, Schwitter J, van Rossum A, et al. Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. International Journal of Cardiology. 2018; 252: 216-219.
[19]	Heiko Pietsch, Felicitas Escher, Ganna Aleshcheva, Christian Baumeier, Lars Morawietz, Albrecht Elsaesser, & Heinz-Peter Schultheiss. (2021). Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. International Journal of Infectious Diseases, 102(70-72), 70-72.
[20]	Dal-Ré, R., Porcher, R., & Gluud, C. (2020). COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results. Basic & Clinical Pharmacology & Toxicology, 127(6), 445-447.
[21]	Siriphanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020; 17(9): 1463-1471.
[22]	Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and Proposed Management of the Acute COVID-1 Cardiovascular Syndrome. Circulation. 2020; 141(23): 1903-1914.